Opin vísindi

Risk of subsequent primary oral cancer in a cohort of 69,460 5-year survivors of childhood and adolescent cancer in Europe : the PanCareSurFup study

Risk of subsequent primary oral cancer in a cohort of 69,460 5-year survivors of childhood and adolescent cancer in Europe : the PanCareSurFup study


Title: Risk of subsequent primary oral cancer in a cohort of 69,460 5-year survivors of childhood and adolescent cancer in Europe : the PanCareSurFup study
Author: Sunguc, Ceren
Hawkins, Michael M
Winter, David L
Dudley, Isabelle M.
Heymer, Emma J.
Teepen, Jop C
Allodji, Rodrigue S
Belle, Fabiën N.
Bagnasco, Francesca
Byrne, Julianne
... 30 more authors Show all authors
Date: 2022
Language: English
Scope:
University/Institute: Landspitali - The National University Hospital of Iceland
Series: British Journal of Cancer; ()
ISSN: 0007-0920
DOI: https://doi.org/10.1038/s41416-022-02016-w
Subject: Oncology; Cancer Research
URI: https://hdl.handle.net/20.500.11815/3664

Show full item record

Citation:

Sunguc , C , Hawkins , M M , Winter , D L , Dudley , I M , Heymer , E J , Teepen , J C , Allodji , R S , Belle , F N , Bagnasco , F , Byrne , J , Bárdi , E , Ronckers , C M , Haddy , N , Guðmundsdóttir , Þ , Garwicz , S , Jankovic , M , van der Pal , H J H , Mazić , M Č , Schindera , C , Grabow , D , Maule , M , Kaatsch , P , Kaiser , M , Fresneau , B , Michel , G , Skinner , R , Wiebe , T , Sacerdote , C , Jakab , Z , Gunnes , M W , Terenziani , M , Winther , J F , Lähteenmäki , P M , Zaletel , L Z , Kuehni , C E , Kremer , L C , Haupt , R , de Vathaire , F , Hjorth , L & Reulen , R C 2022 , ' Risk of subsequent primary oral cancer in a cohort of 69,460 5-year survivors of childhood and adolescent cancer in Europe : the PanCareSurFup study ' , British Journal of Cancer . https://doi.org/10.1038/s41416-022-02016-w

Abstract:

Background: Survivors of childhood cancer are at risk of subsequent primary malignant neoplasms (SPNs), but the risk for rarer types of SPNs, such as oral cancer, is uncertain. Previous studies included few oral SPNs, hence large-scale cohorts are required to identify groups at risks. Methods: The PanCareSurFup cohort includes 69,460 5-year survivors of childhood cancer across Europe. Risks of oral SPNs were defined by standardised incidence ratios (SIRs), absolute excess risks and cumulative incidence. Results: One hundred and forty-five oral SPNs (64 salivary gland, 38 tongue, 20 pharynx, 2 lip, and 21 other) were ascertained among 143 survivors. Survivors were at 5-fold risk of an oral SPN (95% CI: 4.4–5.6). Survivors of leukaemia were at greatest risk (SIR = 19.2; 95% CI: 14.6–25.2) followed by bone sarcoma (SIR = 6.4, 95% CI: 3.7–11.0), Hodgkin lymphoma (SIR = 6.2, 95% CI: 3.9–9.9) and soft-tissue sarcoma (SIR = 5.0, 95% CI: 3.0–8.5). Survivors treated with radiotherapy were at 33-fold risk of salivary gland SPNs (95% CI: 25.3–44.5), particularly Hodgkin lymphoma (SIR = 66.2, 95% CI: 43.6–100.5) and leukaemia (SIR = 50.5, 95% CI: 36.1–70.7) survivors. Survivors treated with chemotherapy had a substantially increased risk of a tongue SPN (SIR = 15.9, 95% CI: 10.6–23.7). Conclusions: Previous radiotherapy increases the risk of salivary gland SPNs considerably, while chemotherapy increases the risk of tongue SPNs substantially. Awareness of these risks among both health-care professionals and survivors could play a crucial role in detecting oral SPNs early.

Description:

Funding Information: The PanCareSurFup consortium and related work was supported by the European Union’s Seventh Framework Programme for research, technological development, and demonstration under grant agreement no. 257505. Additional financial support was received from: The Foundation Force de recherche sur le cancer de l’enfant (FORCE), The Italian Association for Cancer Research and the Compagnia San Paolo; The Fondo Chiara Rama ONLUS; The Swedish Childhood Cancer Fund; the French Association for Cancer Research (ARC); The French National Agency for Research (ANR) (Hope-Epi project); the French National Cancer Institute (INCA); Pfizer Foundation for Children and Adolescent Health; Slovenian Research Agency; the Swiss Paediatric Oncology Group; The Swiss Cancer League (KLS-3412-02-2014, KLS-3886-02-2016, KLS-5432-08-2021); The Swiss Cancer Research foundation (KFS-02783-02-2011, KFS-4157-02-2017, KLA/KFS-4825-01-2019, KFS-4722-02-2019, KFS-5302-02-2021); The Swiss National Science Foundation (PDFMP3_141775), The Dutch Cancer Society (DCOG2011-5027 and UVA2012-5517), The Norwegian Childhood Cancer Foundation, and Children with Cancer UK (grant no: 20457). CS was supported by a studentship from the Turkish Ministry of National Education. Publisher Copyright: © 2022, The Author(s).

Files in this item

This item appears in the following Collection(s)